Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies

Trial Profile

A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisocabtagene-maraleucel (Primary)
  • Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
  • Focus Therapeutic Use
  • Acronyms PILOT; TRANSCENDWORLD
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Dec 2019 Results published in the Bristol-Myers Squibb Media Release
    • 02 Dec 2019 Planned number of patients changed from 124 to 116.
    • 06 Nov 2019 Preliminary (n=10) safety and efficacy data from this study, were released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top